Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Blueprint Medicines (BPMC)
NASDAQ:BPMC
Holding BPMC?
Track your performance easily
BPMC Stock Chart & Stats
Day’s Range― - ―
52-Week Range$72.24 - $121.90
Previous CloseN/A
Volume168.58K
Average Volume (3M)732.37K
Market Cap
$6.60B
Enterprise Value$5.86B
Total Cash (Recent Filing)$214.16M
Total Debt (Recent Filing)$4.31M
Price to Earnings (P/E)―
Beta1.60
Next Earnings
Feb 13, 2025EPS Estimate
-0.69Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.11
Shares Outstanding63,525,837
10 Day Avg. Volume986,457
30 Day Avg. Volume732,366
Standard Deviation0.13
R-Squared0.06
Alpha0.00321
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)15.34
Price to Cash Flow (P/CF)-122.20
P/FCF Ratio0.00
Enterprise Value/Market Cap0.89
Enterprise Value/Revenue13.49
Enterprise Value/Gross Profit24.34
Enterprise Value/Ebitda-55.21
Forecast
1Y Price Target
$122.92Price Target Upside18.25% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering14
Blueprint Medicines News
PremiumCompany Announcements
Blueprint Medicines Highlights 2024 Achievements and Future Growth
Bulls Say, Bears Say
Bulls Say
Financial PerformanceBlueprint Medicines Corporation is projected to reach $4B in peak revenues from the SM franchise alone, with potential revenues of $2B by 2030.
Market PotentialAnalyst reiterates a Market Outperform rating for Blueprint Medicines Corporation, highlighting significant upside potential as an attractive investment opportunity.
Product DevelopmentBLU-808 represents a new growth opportunity for the company that is not currently priced in.
Bears Say
Adverse EffectsThe pooled rate of hair color change is higher than barzo and briquilimab, suggesting potential for higher rates of other on-target adverse effects.
Competitive PositionThe competitive landscape includes several companies developing similar therapies, which could impact Blueprint Medicines' market position.
Revenue GrowthThe price target was reduced to $89 from $97 due to a revised outlook on revenue growth.
---
Ownership Overview
1.53% Insiders
42.63% Mutual Funds
0.26% Other Institutional Investors
38.16% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
BPMC FAQ
What was Blueprint Medicines’s price range in the past 12 months?
Blueprint Medicines lowest stock price was $72.24 and its highest was $121.90 in the past 12 months.
What is Blueprint Medicines’s market cap?
Blueprint Medicines’s market cap is $6.60B.
When is Blueprint Medicines’s upcoming earnings report date?
Blueprint Medicines’s upcoming earnings report date is Feb 13, 2025 which is in 26 days.
How were Blueprint Medicines’s earnings last quarter?
Blueprint Medicines released its earnings results on Oct 30, 2024. The company reported -$0.89 earnings per share for the quarter, beating the consensus estimate of -$0.961 by $0.071.
Is Blueprint Medicines overvalued?
According to Wall Street analysts Blueprint Medicines’s price is currently Undervalued.
Does Blueprint Medicines pay dividends?
Blueprint Medicines does not currently pay dividends.
What is Blueprint Medicines’s EPS estimate?
Blueprint Medicines’s EPS estimate is -0.69.
How many shares outstanding does Blueprint Medicines have?
Blueprint Medicines has 63,525,837 shares outstanding.
What happened to Blueprint Medicines’s price movement after its last earnings report?
Blueprint Medicines reported an EPS of -$0.89 in its last earnings report, beating expectations of -$0.961. Following the earnings report the stock price went up 7.002%.
Which hedge fund is a major shareholder of Blueprint Medicines?
Among the largest hedge funds holding Blueprint Medicines’s share is Woodline Partners LP. It holds Blueprint Medicines’s shares valued at 42M.
---
Blueprint Medicines Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$122.92 (18.25% Upside)
$122.92 (18.25% Upside)
Blogger Sentiment
Bullish
BPMC Sentiment 75%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 768.6K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 7.3%
Last 30 Days ▲ 5.7%
Last 30 Days ▲ 5.7%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
29.09%
12-Months-Change
Fundamentals
Return on Equity
-49.66%
Trailing 12-Months
Asset Growth
8.54%
Trailing 12-Months
Company Description
Blueprint Medicines
Blueprint Medicines Corp. is a precision therapy company. It focuses on medicines to improve the lives of patients with genomically defined cancers, rare diseases and cancer immunotherapy. The company was founded by Chris Varma, Nicholas B. Lydon, Brian Druker, and Alexis Borisy on October 14, 2008 and is headquartered in Cambridge, MA.
---
BPMC Company Deck
---
BPMC Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflects a strong financial and operational performance for Blueprint Medicines, highlighted by significant revenue growth and strategic advancements in the pipeline. Despite some challenges with pricing dynamics in the international markets and potential impacts of free drug policies, the overall outlook remains positive with a focus on sustainable growth and innovation.Read More>---
BPMC Stock 12 Month Forecast
Average Price Target
$122.92
▲(18.25% Upside)
Technical Analysis
Alnylam Pharma
―
FibroGen
―
Revolution Medicines
―
RegenXBio
―
Kura Oncology
―
Sarepta Therapeutics
―
Best Analysts Covering BPMC
1 Year
1 Year Success Rate
12/15 ratings generated profit
1 Year Average Return
+39.99%
reiterated a buy rating 5 days ago
Copying Ami Fadia's trades and holding each position for 1 Year would result in 80.00% of your transactions generating a profit, with an average return of +39.99% per trade.
---